Optum is UnitedHealth Group's pharmacy services unit and said it would buy Diplomat Pharmacy for about $303 million. Diplomat's stock closed Friday's session at $5.81 per share with a market cap at about $441 million.
"Diplomat has a long track record of providing specialty pharmacy and infusion services but has encountered operating difficulties over the last few years," Cantor Fitzgerald analyst Steven Halper wrote in a note. "...The entrance into the PBM market has not panned out as the company probably had hoped. That said, we view the acquisition as a solid move for UNH from both a strategic and financial standpoint."
Diplomat shares were trading down 31.67% at $3.97 in Monday’s pre-market session. The stock has a 52-week high of $16.53 and a 52-week low of $2.43.
Diplomat's stock has crashed twice in 2019 amid warnings the company could not continue as a going concern. Shares fell from around $13.70 to $5.87 in late February, and again from $6.20 to $3.10 in early November.
Synthorx To Be Acquired By Sanofi For .5B
ArQule To Be Acquired By Merck For .7B
Latest Ratings for UNH
|Dec 2019||Reiterates||Strong Buy|
View More Analyst Ratings for UNH
View the Latest Analyst Ratings
See more from Benzinga
- Synthorx To Be Acquired By Sanofi For .5B
- ArQule To Be Acquired By Merck For .7B
- Opinion | How Tokyo Could Overtake Hong Kong As Asia's Financial Capital
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.